Celularity Inc. (NASDAQ:CELU) Short Interest Update

Celularity Inc. (NASDAQ:CELU) was the target of a significant growth in short interest in February. As of February 28th, there was short interest totalling 1,040,000 shares, a growth of 261.9% from the February 13th total of 287,400 shares. Currently, 8.3% of the company’s shares are sold short. Based on an average daily trading volume, of 170,300 shares, the days-to-cover ratio is currently 6.1 days.

Celularity Price Performance

Shares of CELU opened at $1.55 on Friday. The company’s 50-day simple moving average is $1.92 and its 200-day simple moving average is $2.30. Celularity has a 1 year low of $1.00 and a 1 year high of $5.91.

Institutional Investors Weigh In On Celularity

Large investors have recently modified their holdings of the company. Keynote Financial Services LLC lifted its holdings in Celularity by 90.1% during the 4th quarter. Keynote Financial Services LLC now owns 25,023 shares of the company’s stock worth $52,000 after buying an additional 11,863 shares during the last quarter. C V Starr & Co. Inc. purchased a new stake in Celularity during the fourth quarter worth approximately $1,589,000. Biltmore Family Office LLC acquired a new position in Celularity in the fourth quarter valued at approximately $73,000. Finally, Two Sigma Investments LP purchased a new position in Celularity in the fourth quarter valued at approximately $93,000. 19.02% of the stock is owned by hedge funds and other institutional investors.

Celularity Company Profile

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.